Xencor to Participate at Upcoming Investor Conferences

November 24, 2026

PASADENA, Calif.--(BUSINESS WIRE)--Nov. 24, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at upcoming investor conferences:

- **9th Annual Evercore Healthcare Conference**
  Date: Monday, November 30, 2026

- **Piper Sandler 38th Annual Healthcare Conference**
  Date: Tuesday, December 1, 2026
  Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT

A live webcast of the Piper Sandler presentation will be available under “Events & Presentations” in the Investors section of Xencor’s website located at www.xencor.com. A replay of the event will be available for at least 30 days following the presentation.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor’s XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261124935540/en/

Charles Liles
cliles@xencor.com
(626) 483-3772

Source: Xencor, Inc.